# Simvastatin in Waldenstrom's Macroglobulinemia

> **NCT00575965** · PHASE2 · TERMINATED · sponsor: **Dana-Farber Cancer Institute** · enrollment: 18 (actual)

## Conditions studied

- Waldenstrom's Macroglobulinemia

## Interventions

- **DRUG:** Simvastatin

## Key facts

- **NCT ID:** NCT00575965
- **Lead sponsor:** Dana-Farber Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2007-11
- **Primary completion:** 2011-12
- **Final completion:** 2011-12
- **Target enrollment:** 18 (ACTUAL)
- **Why stopped:** Slow accrual led to early study termination.
- **Last updated:** 2015-12-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00575965

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00575965, "Simvastatin in Waldenstrom's Macroglobulinemia". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00575965. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*